ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer

IF 6.4 1区医学 Q1 ONCOLOGY

British Journal of Cancer Pub Date : 2025-03-15 DOI:10.1038/s41416-025-02971-0

Adrien Grancher, Ludivine Beaussire-Trouvay, Virginie Vernon, Marie Dutherage, Valérie Blondin, Caroline Elie, Karine Bouhier-Leporrier, Marie-Pierre Galais, Tifenn Clabaut, Anne-Laure Bignon, Aurélie Parzy, Alice Gangloff, Lilian Schwarz, Emilie Lévêque, Jean-Christophe Sabourin, Pierre Michel, Nasrin Vasseur, David Sefrioui, André Gilibert, Frédéric Di Fiore

{"title":"ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer","authors":"Adrien Grancher, Ludivine Beaussire-Trouvay, Virginie Vernon, Marie Dutherage, Valérie Blondin, Caroline Elie, Karine Bouhier-Leporrier, Marie-Pierre Galais, Tifenn Clabaut, Anne-Laure Bignon, Aurélie Parzy, Alice Gangloff, Lilian Schwarz, Emilie Lévêque, Jean-Christophe Sabourin, Pierre Michel, Nasrin Vasseur, David Sefrioui, André Gilibert, Frédéric Di Fiore","doi":"10.1038/s41416-025-02971-0","DOIUrl":null,"url":null,"abstract":"Circulating tumor DNA variations (∆ctDNA) were reported to be associated with treatment efficacy in metastatic colorectal cancer (mCRC). The present study evaluated ∆ctDNA according to first-line treatment intensity. Patients from two prospective ctDNA collections were divided into Group ≤ 2 drugs and Group ≥ 3 drugs. ∆ctDNA were analysed from baseline to cycle 3 or 4 (C3-4) according to three predefined subgroups: ∆ctDNA ≥ 80%_ undetectable, ∆ctDNA ≥ 80%_ detectable, and ∆ctDNA < 80%. Impact of ∆ctDNA on progression-free survival (PFS) and overall survival (OS) were analysed. Pretreatment ctDNA was detected in 129/152 (84.9%) of patients. A ∆ctDNA ≥ 80%_undetectable was more frequent in Group ≥ 3 than ≤ 2 drugs (respectively 51.5% vs. 32.7%, p = 0.015). Patients with ∆ctDNA ≥ 80%_undetectable had longer survival than other ∆ctDNA subgroups, in Group ≥ 3 drugs (mPFS 11.5 vs 7.8 vs 6.3 months, p = 0.02: mOS 30.2 vs 18.1 vs 16.4 month, p = 0.04) and in Group ≤ 2 drugs (mPFS 8.4 vs 6.0 vs 5.3 months, p = 0.05; mOS 29.6 vs 14.6 vs 14.6 months, p = 0.007). Early ∆ctDNA are associated to treatment intensity in first line mCRC with a significant impact on prognosis.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"132 9","pages":"814-821"},"PeriodicalIF":6.4000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41416-025-02971-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Circulating tumor DNA variations (∆ctDNA) were reported to be associated with treatment efficacy in metastatic colorectal cancer (mCRC). The present study evaluated ∆ctDNA according to first-line treatment intensity. Patients from two prospective ctDNA collections were divided into Group ≤ 2 drugs and Group ≥ 3 drugs. ∆ctDNA were analysed from baseline to cycle 3 or 4 (C3-4) according to three predefined subgroups: ∆ctDNA ≥ 80%_ undetectable, ∆ctDNA ≥ 80%_ detectable, and ∆ctDNA < 80%. Impact of ∆ctDNA on progression-free survival (PFS) and overall survival (OS) were analysed. Pretreatment ctDNA was detected in 129/152 (84.9%) of patients. A ∆ctDNA ≥ 80%_undetectable was more frequent in Group ≥ 3 than ≤ 2 drugs (respectively 51.5% vs. 32.7%, p = 0.015). Patients with ∆ctDNA ≥ 80%_undetectable had longer survival than other ∆ctDNA subgroups, in Group ≥ 3 drugs (mPFS 11.5 vs 7.8 vs 6.3 months, p = 0.02: mOS 30.2 vs 18.1 vs 16.4 month, p = 0.04) and in Group ≤ 2 drugs (mPFS 8.4 vs 6.0 vs 5.3 months, p = 0.05; mOS 29.6 vs 14.6 vs 14.6 months, p = 0.007). Early ∆ctDNA are associated to treatment intensity in first line mCRC with a significant impact on prognosis.

Abstract Image

查看原文本刊更多论文

一线转移性结直肠癌治疗强度对ctDNA的影响。

背景：据报道，循环肿瘤DNA变异（∆ctDNA）与转移性结直肠癌（mCRC）的治疗效果有关。本研究根据一线治疗强度评估∆ctDNA。方法：两组前瞻性ctDNA采集患者分为≤2药物组和≥3药物组。从基线到第3或第4周期（C3-4），根据三个预定义的亚组分析∆ctDNA:∆ctDNA≥80%_不可检测，∆ctDNA≥80%_可检测，∆ctDNA < 80%。分析∆ctDNA对无进展生存期（PFS）和总生存期（OS）的影响。结果：152例患者中有129例（84.9%）检测到预处理ctDNA。≥3组A∆ctDNA≥80%_undetectable发生率高于≤2组（分别为51.5% vs. 32.7%, p = 0.015）。≥3种药物组（mPFS 11.5个月vs 7.8个月vs 6.3个月，p = 0.02; mOS 30.2个月vs 18.1个月vs 16.4个月，p = 0.04）和≤2种药物组(mPFS 8.4个月vs 6.0个月vs 5.3个月，p = 0.05；mo29.6 vs 14.6 vs 14.6个月，p = 0.007)。讨论：一线mCRC早期∆ctDNA与治疗强度相关，对预后有显著影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Cancer 医学-肿瘤学

CiteScore

15.10

自引率

1.10%

发文量

383

审稿时长

6 months

期刊介绍： The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.